**Supplemental Table 1. Antibody Response Following Third Dose of BNT162b2**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   | **All patients** | **Age 5-11y** | **Age 12-15y** | **Age 16-17y** | P value |
| **n** | **-** | **n** |  | **n** |  | **n** |  |
| Number of patients | 53 |   | 14 |   | 19 |   | 20 |   |   |
| Detectable anti-RBD antibody(n, % positive) |  53 | 100%  | 14 | 100% | 19 |  100% | 20 | 100%  | 0.429 |
| Time from third dose to antibody test (days, median, IQR) | 45.0 | 23.0 ,52.0 | 18.0 | 8.0 ,21.0 | 48.0 | 42.0 ,51.0 | 51.5 | 43.5 ,54.5 | <0.001 |
| Anti-RBD IgG level(ug/mL, Mean, SD) | 102.9 | 76.00 | 92.0 | 54.78 | 100.8 | 67.97 | 112.6 | 95.85 | 0.738 |
| Anti-RBD IgG level(ug/mL, Median, IQR) | 97.0 | 42.0 ,135.0 | 97.0 | 68.0 ,106.0 | 97.0 | 42.0 ,133.0 | 90.0 | 28.5 ,181.5 | 0.963 |
| Patients with antibody level following both 2nd and booster dose | 36 | 68% | 0 |  | 16 |  | 20 |  |  |
| Anti-RBD IgG level post-2nd dose (Mean, SD) | 29.7 | 41.93 |  |  | 35.9 | 51.59 | 24.7 | 32.85 | 0.433 |
| Anti-RBD IgG level post-2nd dose (Median, IQR) | 17.0 | 9.9, 32.0 |  |  | 20.5 | 14.5, 35.0 | 14.5 | 7.7, 29.5 | 0.192 |
| Anti-RBD IgG level post-booster (Mean, SD) | 108.0 | 85.82 |  |  | 102.3 | 74.06 | 112.6 | 95.85 | 0.727 |
| Anti-RBD IgG level post-booster (Median IQR) | 97.0 | 29.5, 166.5 |  |  | 97.0 | 37.0, 134.0 | 90.0 | 28.5, 181.5 | 0.937 |
| Delta anti-RBD IgG level (Mean, SD) | 78.3 | 70.43 |  |  | 66.4 | 62.22 | 87.9 | 76.58 | 0.371 |
| Delta anti-RBD IgG level (Median, IQR) | 56.5 | 14.0, 143.9 |  |  | 56.4 | 12.5, 98.0 | 56.5 | 14.0, 158.0 | 0.399 |
| Time from dose 2 to dose 3(in days, Mean, SD) | 112.2 | 60.71 | 47.6 | 9.49 | 114.7 | 50.67 | 155.0 | 50.86 | <0.001\* |
| Time from dose 2 to dose 3 (in days, median, IQR) | 106.0 | 54.0, 164.0 | 44.5 | 41.0, 53.0 | 122.0 | 77.0, 154.0 | 157.0 | 116.5, 193.0 | <0.001\* |
| Medication Treatment (% yes) |  |  |  |  |  |  |  |  |  |
|  No medical therapy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |  |
|  Corticosteroid | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 5 | 0.431 |
|  Anti-TNF monotherapy | 32 | 60 | 9 | 64 | 12 | 63 | 11 | 55 | 0.822 |
|  Anti-TNF and immunomodulator | 11 | 21 | 3 | 21 | 4 | 21 | 4 | 20 | 0.994 |
|  Thiopurine monotherapy | 2 | 4 | 0 | 0 | 1 | 5 | 1 | 5 | 0.688 |
|  Methotrexate monotherapy | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 5 | 0.431 |
|  Mesalamine/sulfasalazine (any) | 5 | 9 | 1 | 7 | 4 | 21 | 0 | 0 | 0.075 |
|  Budesonide | 3 | 6 | 0 | 0 | 2 | 11 | 1 | 5 | 0.428 |
|  Vedolizumab | 1 | 2 | 1 | 7 | 0 | 0 | 0 | 0 | 0.242 |
|  Ustekinumab | 6 | 11 | 1 | 7 | 2 | 11 | 3 | 15 | 0.769 |
|  Tofacitinib | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |  |